<DOC>
	<DOC>NCT00293059</DOC>
	<brief_summary>The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.</brief_summary>
	<brief_title>Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Women 18 years or older With diagnosis of dysfunctional uterine bleeding without organic pathology And with at least one of the following symptoms: prolonged, frequent, or excessive bleeding The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study. Women with history of endometrial ablation or dilatation or curettage within 2 months prior to study start will be excluded.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Dysfunctional Uterine Bleeding</keyword>
</DOC>